Total trials
54
Active
3
Phase 3
14
Total enrollment
4,392
Pipeline matrix
Showing 2 of 2 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Berotralstat | — | — | — | — | 3 | ||
| BCX17725 | — | — | — | — | — | 1 |
Next readouts
- 2024-09-11
- 2026-10
- 2031-08
Top conditions
- Hereditary Angioedema14
- Influenza7
- HAE6
- Lymphoma4
- Gout4
- Paroxysmal Nocturnal Hemoglobinuria4
- Hyperuricemia2
- Arthritis2
Frequently asked questions about BioCryst Pharmaceuticals
- How many clinical trials does BioCryst Pharmaceuticals have on ClinicalTrials.gov?
- BioCryst Pharmaceuticals is listed as the lead sponsor on 54 clinical trials in ClinicalTrials.gov, 3 of which are currently active (recruiting, enrolling, or ongoing).
- How many of BioCryst Pharmaceuticals's trials are in Phase 3?
- 14 of BioCryst Pharmaceuticals's trials are in Phase 3, spread across 2 active drug programs.
- What therapeutic areas does BioCryst Pharmaceuticals focus on?
- BioCryst Pharmaceuticals's most-studied conditions on ClinicalTrials.gov are Hereditary Angioedema, Influenza, HAE, Lymphoma, Gout.
- When are BioCryst Pharmaceuticals's next clinical trial readouts?
- BioCryst Pharmaceuticals has 3 upcoming primary-completion readouts tracked here; the soonest is “Berotralstat Treatment in Children With Hereditary Angioedema”, expected around 2024-09-11.